ACP-01 Phase II Clinical Trial
Hemostemix is currently conducting a randomized, double-blind, placebo-controlled Phase 2 clinical trial for patients with critical limb ischemia at sites in the Canada and United States.
33 control
66 treated
Target Patients
- Diagnosed with CLI
- No treatment options
- Controlled levels in blood sugar, blood pressure, cholesterol
- No previous amputations above the ankle on target limb
Data collection
adverse
events
failure¹
qualityof life
¹Clinical endpoints, as defined by treatment failure, are major amputation (above the talus, 2x wound size, de novo gangrene
How to Participate in the ACP-01 Clinical Trial
For information about participating in the clinical trial please contact
Clinical Trial Manager
trial@hemostemix.com